A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors

Inclusion Criteria:

• At least age of 18 years at screening.
• Patients of advanced solid tumor，who have progressed on or intolerant to standard therapy.
• With measurable lesion according to RECIST 1.1.
• Agree to provide fresh or archival tumor tissue.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1.

Exclusion Criteria:

• Previous or current treatment with KRAS G12D inhibitors.
• Uncontrolled pleural, ascites or pericardial effusion.
• Known and untreated, or active central nervous system metastases.
• History of other primary malignant tumors.
• Serious, uncontrolled, or active comorbidities.
• Refractory nausea, vomiting, or chronic gastrointestinal diseases, or inability to swallow oral medications.